ALPINE IMMUNE SCIENCES, INC.
ALPN evidence brief
What we can confirm
- BioSniper Score:
- 5.3 / 10
- Lead Asset:
- alpn-101 (Phase 2)
What it means
What to watch
Prepared research question
What matters most for ALPN—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Market Cap
—
Cash Runway
—
Lead Asset
alpn-101 (Phase 2)
Next Catalyst
—
Tracking 2 pipeline candidates · 1 clinical trial for ALPINE IMMUNE SCIENCES, INC..
Run ALPINE IMMUNE SCIENCES, INC. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available ALPINE IMMUNE SCIENCES, INC. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Score breakdownBased on 2 of 6 signals · derived from public data
Cash runway data unavailable
Financial health data unavailable
Lead: Phase 1/Phase 2
2 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Regulatory
Frequently asked questions
What is ALPINE IMMUNE SCIENCES, INC.'s lead drug candidate?
ALPINE IMMUNE SCIENCES, INC.'s most advanced tracked candidate is alpn-101 (Phase 2) for systemic lupus erythematosus.
Who is the CEO of ALPINE IMMUNE SCIENCES, INC.?
Mitchell H. Gold, M.D. is the chief executive officer of ALPINE IMMUNE SCIENCES, INC. (ALPN).
What therapeutic areas does ALPINE IMMUNE SCIENCES, INC. focus on?
ALPINE IMMUNE SCIENCES, INC. develops therapies across Oncology, Immunology, Hematology, Nephrology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.